Allergies – Pipeline Review, H2 2012

Published by: Global Markets Direct

Published: Aug. 31, 2012 - 327 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Allergies Overview
Therapeutics Development
An Overview of Pipeline Products for Allergies
Allergies Therapeutics under Development by Companies
Allergies Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Allergies Therapeutics – Products under Development by Companies
Allergies Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Allergies Therapeutics Development
Alcon, Inc.
Shionogi & Co., Ltd.
AstraZeneca PLC
Biotec Pharmacon ASA
Merck & Co., Inc.
AbGenomics International, Inc.
United Biomedical, Inc.
Pharming Group N.V.
BioLineRx, Ltd.
Novartis AG
Actelion Ltd
ALK-Abello A/S
Dyax Corp.
Japan Tobacco Inc.
Taiho Pharmaceutical Co., Ltd.
ViroPharma Incorporated
Shire Plc
DBV Technologies
Allergy Therapeutics plc
Idera Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
CSL Limited
NeoStem, Inc.
Pharmacyclics, Inc.
Stallergenes S.A.
Choongwae Pharma Corp
Sirion Therapeutics, Inc.
Proteo, Inc.
ActogeniX NV
Allergopharma Joachim Ganzer KG
Immupharma Plc
7TM Pharma A/S
Cosmix Molecular Biologicals GmbH
Circassia Holdings Ltd.
Oxagen Limited
EpiVax, Inc.
Indus Biotech Private Limited
Vantia Therapeutics
ImVisioN Therapeutics AG
Xencor, Inc.
iBio, Inc.
Genetic Immunity, LLC
Laboratorios LETI S.L.
ANERGIS SA
Viromed Co., Ltd.
SIFI Pharma
REGiMMUNE Corporation
Immunomic Therapeutics, Inc.
Vifor Pharma Ltd.
Selecta Biosciences, Inc.
Interprotein Corporation
ImmunoFrontier, Inc.
Biomay AG
Vaxine Pty Ltd
RaQualia Pharma Inc.
ToleroTech Inc.
Allergies – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Drug Profiles
DX-88 - Drug Profile
IMO-2134 - Drug Profile
PCI-45261 - Drug Profile
Drug Targeting IL-4 - Drug Profile
TM30510 - Drug Profile
AbGn-168H - Drug Profile
ADC3680B - Drug Profile
Icatibant - Drug Profile
Pollinex Quattro Japanese Cedar - Drug Profile
Sublingual MPL - Drug Profile
Pollinex Quattro Tree - Drug Profile
Pollinex Quattro Ragweed - Drug Profile
Pollinex Quattro Grass - Drug Profile
Pollinex Quattro Grass - Drug Profile
Cinryze - Drug Profile
Cinryze - Drug Profile
Cinryze - Drug Profile
AM461 - Drug Profile
ActoGeniX For Allergic Disease - Drug Profile
Norketotifen - Drug Profile
INDUS82010 - Drug Profile
Leech-Derived Protein Inhibitor - Drug Profile
PKal Inhibitor - Drug Profile
Allergen Extract Of Phleum Pratense - Drug Profile
S-555739 - Drug Profile
ToleroMune House Dust Mite T Cell Vaccine - Drug Profile
Mitizax - Drug Profile
Mitizax - Drug Profile
AM211 - Drug Profile
OM-197-MP-AC - Drug Profile
Birch Pollen Allergoid - Drug Profile
ACTAIR - Drug Profile
CWF-0808 - Drug Profile
ToleroMune Ragweed Allergy T-cell Vaccine - Drug Profile
SF 107 - Drug Profile
IgE Inhibitor - Drug Profile
Zinc Regulator - Drug Profile
Omalizumab - Drug Profile
HOE 140 - Drug Profile
Soluble Beta Glucan - Drug Profile
Omalizumab - Drug Profile
MK-7243 - Drug Profile
MK-8237 - Drug Profile
Xolair - Drug Profile
Ecallantide - Drug Profile
ToleroMune Grass Allergy T-cell Vaccine - Drug Profile
ToleroMune Cat Allergy T Cell Vaccine - Drug Profile
Grazax - Drug Profile
Grazax - Drug Profile
Phleum Pratense - Drug Profile
ALK Ragweed Vaccine - Drug Profile
AL0206st - Drug Profile
Acaroid - Drug Profile
IPP-201007 - Drug Profile
ViaSkin Peanut - Drug Profile
ViaSkin Peanut - Drug Profile
Dermatophagoides Farinae Allergen Extract - Drug Profile
IVN201 - Drug Profile
Trichuris Suis Ova - Drug Profile
Ketorolac - Drug Profile
gpASIT + TM - Drug Profile
Oralair - Drug Profile
Ruconest - Drug Profile
Ruconest - Drug Profile
RQ-00000008 - Drug Profile
ALK Birch Pollen Vaccine - Drug Profile
Epicutaneous Allergen Patch - Drug Profile
IVN-Birch - Drug Profile
IVN-Mite - Drug Profile
DermAll Vaccine - Drug Profile
Novel Immunotherapeutics - Drug Profile
PG-102 - Drug Profile
RGI-1001 - Drug Profile
UBI IgE Allergy Vaccine - Drug Profile
Icatibant - Drug Profile
HOE-140 - Drug Profile
XmAb7195 - Drug Profile
Ragweed Sublingual Immunotherapy Tablet - Drug Profile
Grass Pollen Allergen B-Cell Peptide Vaccine - Drug Profile
Birch Pollen Allergen Peptide Carrier Fusion Vaccine - Drug Profile
House Dust Mite Peptide Carrier Fusion Vaccine - Drug Profile
Mould Allergen B-Cell Peptide Vaccine - Drug Profile
Cat Allergen Peptide Carrier Fusion Vaccine - Drug Profile
Dog Allergen B-Cell Peptide Vaccine - Drug Profile
Olive Allergen B-Cell Peptide Vaccine - Drug Profile
Birch Allergen RNA Vaccine - Drug Profile
Grass Allergen RNA Vaccine - Drug Profile
Ragweed Allergen RNA Vaccine - Drug Profile
House Dust Mite RNA Vaccine - Drug Profile
Japanese Cedar RNA Vaccine - Drug Profile
Cat Allergen RNA Vaccine - Drug Profile
Fish Allergen Hypoallergenic Vaccine - Drug Profile
BM32 - Drug Profile
Ragweed Allergen Hypoallergenic Vaccine - Drug Profile
House Dust Mite Hypoallergenic Vaccine - Drug Profile
Japanese Cedar Hypoallergenic Vaccine - Drug Profile
Cat Allergen Hypoallergenic Vaccine - Drug Profile
Parietaria Allergen Hypoallergenic Vaccine - Drug Profile
Mugwort Allergen Hypoallergenic Vaccine - Drug Profile
Birch Allergen Specific IgG - Drug Profile
Grass Allergen Specific IgG - Drug Profile
TAC-201 - Drug Profile
ToleroMune Birch Allergy T Cell Vaccine - Drug Profile
ToleroMune Alternaria Allergy T Cell Vaccine - Drug Profile
ToleroMune Japanese Cedar Allergy T Cell Vaccine - Drug Profile
ToleroMune Dog Allergy T Cell Vaccine - Drug Profile
Cinryze + rHuPH20 - Drug Profile
Bet V 1AF1-Alum + Bet V 1AF2-Alum - Drug Profile
Fve Polypeptide - Drug Profile
BCX4161 - Drug Profile
QGE-031 - Drug Profile
AL53817 - Drug Profile
Cytokine-Like Proteins - Drug Profile
JDP-207 - Drug Profile
Anti-Allergy siRNA - Drug Profile
CRTH2 Receptor Antagonist - Drug Profile
Athelos - Drug Profile
Insect Bite Allergy Vaccine - Drug Profile
JTE-051 - Drug Profile
Grass Hypoallergenic Vaccine - Drug Profile
AZ12441970 - Drug Profile
SM-324405 - Drug Profile
C1-Esterase Inhibitor - Drug Profile
C1-INH - Drug Profile
EDP 14 - Drug Profile
GE2 - Drug Profile
DX-2930 - Drug Profile
ARA-LAMP Vax - Drug Profile
MULTI-LAMP Vax - Drug Profile
t2SVP For Allergy - Drug Profile
OC-499 - Drug Profile
brompheniramine - Drug Profile
AllerG - Drug Profile
AllerR - Drug Profile
AllerJ - Drug Profile
AllerDM - Drug Profile
Allergies Therapeutics – Drug Profile Updates
Allergies Therapeutics – Discontinued Products
Allergies Therapeutics - Dormant Products
Allergies – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Allergies, H2 2012
Products under Development for Allergies – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Development by Companies, H2 2012 (Contd..1)
Number of Products under Development by Companies, H2 2012 (Contd..2)
Number of Products under Development by Companies, H2 2012 (Contd..3)
Number of Products under Development by Companies, H2 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Development by Companies, H2 2012 (Contd..1)
Products under Development by Companies, H2 2012 (Contd..2)
Products under Development by Companies, H2 2012 (Contd..3)
Products under Development by Companies, H2 2012 (Contd..4)
Products under Development by Companies, H2 2012 (Contd..5)
Products under Development by Companies, H2 2012 (Contd..6)
Products under Development by Companies, H2 2012 (Contd..7)
Products under Development by Companies, H2 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2012
Alcon, Inc., H2 2012
Shionogi & Co., Ltd., H2 2012
AstraZeneca PLC, H2 2012
Biotec Pharmacon ASA, H2 2012
Merck & Co., Inc., H2 2012
AbGenomics International, Inc., H2 2012
United Biomedical, Inc., H2 2012
Pharming Group N.V., H2 2012
BioLineRx, Ltd., H2 2012
Novartis AG, H2 2012
Actelion Ltd, H2 2012
ALK-Abello A/S, H2 2012
Dyax Corp., H2 2012
Japan Tobacco Inc., H2 2012
Taiho Pharmaceutical Co., Ltd., H2 2012
ViroPharma Incorporated, H2 2012
Shire Plc, H2 2012
DBV Technologies, H2 2012
Allergy Therapeutics plc, H2 2012
Idera Pharmaceuticals, Inc., H2 2012
Elite Pharmaceuticals, Inc., H2 2012
BioCryst Pharmaceuticals, Inc., H2 2012
CSL Limited, H2 2012
NeoStem, Inc., H2 2012
Pharmacyclics, Inc., H2 2012
Stallergenes S.A., H2 2012
Choongwae Pharma Corp, H2 2012
Sirion Therapeutics, Inc., H2 2012
Proteo, Inc., H2 2012
ActogeniX NV, H2 2012
Allergopharma Joachim Ganzer KG, H2 2012
Immupharma Plc, H2 2012
7TM Pharma A/S, H2 2012
Cosmix Molecular Biologicals GmbH, H2 2012
Circassia Holdings Ltd., H2 2012
Oxagen Limited, H2 2012
EpiVax, Inc., H2 2012
Indus Biotech Private Limited, H2 2012
Vantia Therapeutics, H2 2012
ImVisioN Therapeutics AG, H2 2012
Xencor, Inc., H2 2012
iBio, Inc., H2 2012
Genetic Immunity, LLC, H2 2012
Laboratorios LETI S.L., H2 2012
ANERGIS SA, H2 2012
Viromed Co., Ltd., H2 2012
SIFI Pharma, H2 2012
REGiMMUNE Corporation, H2 2012
Immunomic Therapeutics, Inc., H2 2012
Vifor Pharma Ltd., H2 2012
Selecta Biosciences, Inc., H2 2012
Interprotein Corporation, H2 2012
ImmunoFrontier, Inc., H2 2012
Biomay AG, H2 2012
Vaxine Pty Ltd, H2 2012
RaQualia Pharma Inc., H2 2012
ToleroTech Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Allergies Therapeutics – Drug Profile Updates
Allergies Therapeutics – Discontinued Products
Allergies Therapeutics – Dormant Products
Allergies Therapeutics – Dormant Products (Contd..1)
List of Figures
Number of Products under Development for Allergies, H2 2012
Products under Development for Allergies – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012

Abstract

Allergies – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Allergies - Pipeline Review, H2 2012', provides an overview of the Allergies therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergies. 'Allergies - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Allergies.
  • A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Allergies pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Allergies.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Allergies pipeline depth and focus of Allergies therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.